Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren's Syndrome
-- Only Sjögren’s syndrome Phase 2 trial to meet the primary endpoint in both patient population types -- -- Patients with moderate-to-severe systemic disease activity treated with... | May 31, 2023